NCT02000830View on ClinicalTrials.gov

Follow up Study of Patients Having Participated in Clinical Trial 64,185-204

CompletedOBSERVATIONAL
Enrollment

68

Participants

Timeline

Start Date

October 17, 2013

Primary Completion Date

February 28, 2020

Study Completion Date

February 28, 2020

Conditions
Hyperbilirubinemia, Neonatal
Interventions
DRUG

Stannsoporfin

Stannsoporfin administered by intramuscular (IM) injection

DRUG

Placebo

Matching placebo administered by IM injection

All Listed Sponsors
lead

InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company

INDUSTRY

NCT02000830 - Follow up Study of Patients Having Participated in Clinical Trial 64,185-204 | Biotech Hunter | Biotech Hunter